BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

TLC appoints George Spencer-Green as CMO

February 5, 2019 | News

With more than three decades of clinical medicine and drug development experience, Dr. Spencer-Green will serve as a member of the TLC Management Team and guide the company in its clinical and regulatory activities

Taiwan Liposome Company, a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, today announced the appointment of George Spencer-Green, MD, MS, as TLC's new Chief Medical Officer. With more than three decades of clinical medicine and drug development experience, Dr. Spencer-Green will serve as a member of the TLC Management Team and guide the company in its clinical and regulatory activities.

"We are thrilled to welcome Dr. Spencer-Green to the TLC family and look forward to his capable leadership as we transition into a late-stage company with the advancement of our osteoarthritis program through the clinic," commented TLC President George Yeh. "As Chief Medical Officer, Dr. Spencer-Green will play an integral role in the clinical development strategies of all our programs. I am confident that his expertise will help guide the advancement of our clinical trial designs and executions."

"As TLC is at an important stage in its growth, I'm extremely excited to join TLC and help lead the continued development of its strong pipeline," said Dr. Spencer-Green. "The statistical significant findings of durable pain relief shown in the Phase 2 trial for TLC599 in osteoarthritis demonstrate a promising and differentiated treatment profile. I believe TLC599 is uniquely positioned to address unmet needs for the treatment of osteoarthritis pain. I look forward to advancing the company's ongoing clinical trials for its lead programs in pain management, as well as initiating other programs in ophthalmology and oncology."

Dr. Spencer-Green brings with him experience as the prior Vice President and clinical head of Pfizer's biosimilars development program, where he led the team that designed and initiated clinical development plans from Phase 1 to Phase 3 for five assets. Prior to Pfizer, he served as the Senior Medical Director at Vertex Pharmaceuticals, where he led the design and execution of clinical development programs in rheumatoid arthritis and cystic fibrosis. Prior to Vertex, he was the Global Medical Director at Abbott Laboratories, and was the clinical lead for the rheumatoid arthritis registration and long-term extension programs for Humira. At Immunex Corporation, where he worked prior to Abbott Laboratories, he was Franchise Medical Director for Enbrel, the first targeted biologic treatment approved for the treatment of rheumatoid arthritis.